Meijboom KE, Abdallah A, Fordham NP, Nagase H, Rodriguez T, Kraus C, Gendron TF, Krishnan G, Esanov R, Andrade NS, Rybin MJ, Ramic M, Stephens ZD, Edraki A, Blackwood MT, Kahriman A, Henninger N, Kocher JA, Benatar M, Brodsky MH, Petrucelli L, Gao FB, Sontheimer EJ, Brown RH, Zeier Z, Mueller C. CRISPR/Cas9-mediated excision of ALS/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro. Nat Commun. 2022 Oct 21;13(1):6286. [PubMed link]
Recent Posts
- Landmark Study Identifies Novel Pre-Symptomatic Biomarkers and Accelerates Progress Towards ALS Prevention
- July 26, 2026: Miami Marlins Game
- Feature: UHealth’s Qalsody Clinic Provides Cutting-Edge Care for ALS Patients
- The New York Times Feature: In a Milestone for A.L.S., a Treatment Helps Some Patients Improve
- CReATe Author Series Ep. 18 – Dr. Michael Benatar on MMI as a prodromal stage of ALS
Recent Comments